Date of report 30 May 2024
Reported case interaction between
Bictegravir and Cytisine
Bictegravir and Cytisine
Drugs suspected to be involved in the DDI
Complete list of drugs taken by the patient
Cytisine
Clinical case description
A 58-year-old male with an HIV infection known since 2018, had an undetectable viral load while on stable treatment with BIC/F/TAF. In March 2024, the patient started taking cytisine for smoking cessation, initially with six 1.5 mg tablets per day for five days before stopping smoking, and gradually reducing the dose to two tablets per day over 25 days, as recommended in the prescribing information. No adverse events occurred while on treatment with cytisine. The HIV plasma viral load remains <20 copies/mL.
Clinical Outcome
Editorial Comment
Cytisine is becoming widely used for smoking cessation. It is primarily excreted renally as an unchanged drug. There are no reports of CYP or transporter involvement on cytisine pharmacokinetics, making clinically significant interactions with antiretroviral treatment unlikely.
University of Liverpool Recommendation
No clinically significant interaction expected